CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology
Also helping in the fight against coronavirus (COVID-19)
What Avalon GloboCare does:
Avalon GloboCare Corp (NASDAQ:AVCO) specializes in developing cell-based technologies but is also involved in the management of stem-cell banks and clinical laboratories and the fight against coronavirus (COVID-19).
Via its two platforms, Avalon Cell and Avalon Rehab, the company develops proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology. It markets proprietary exosome isolation systems and related products to hospitals.
In layman’s terms, exosomes are akin to powerful messengers (tiny, membrane-bound vesicles) released by cells into biofluids like plasma/serum, urine, and saliva.